博瑞医药：BGM1812注射液获美国FDA药品临床试验批准

Core Viewpoint - The company has received FDA approval to initiate Phase I clinical trials for BGM1812 injection, aimed at treating overweight or obesity [1] Group 1: Product Details - BGM1812 injection is a newly designed long-acting Amylin analog with good molecular activity and pharmaceutical stability [1] - Amylin is a satiety hormone composed of 37 amino acids, released by pancreatic beta cells in conjunction with insulin [1] Group 2: Mechanism of Action - The drug activates brain pathways that promote satiety, suppresses appetite, delays gastric emptying, and inhibits glucagon secretion, contributing to its weight loss mechanisms [1]